Bantam Pharmaceutical
June 22, 2026
Theater 2
Type: Company Presentation
Focus Area:
Oncology
Based in Research Triangle Park, NC, Bantam Pharmaceutical is a clinical-stage company pioneering mitochondrial biology to develop first-in-class small molecule therapeutics for treating aggressive cancers after standard-of-care (SoC) therapies fail. The company currently holds two active Investigational New Drug (IND) applications in the U.S. and a Clinical Trial Application (CTA) in Canada for its lead candidate, BTM-3566, targeting B-cell malignancies and select solid tumors. Bantam seeks to raise up to $40 million to advance BTM-3566 to clinical proof of concept, anticipating an exit via a licensing or an M&A transaction with a BioPharma company within 2 to 3 years.
Company HQ City:
Research Triangle Park
Company HQ State:
NC
Company HQ Country:
United States
Year Founded:
2015
Lead Product in Development:
BTM-3566
CEO
Michael Stocum
Development Phase of Lead Product
Phase I
Number of Unlicensed Products Looking for Licensing
1
When you expect your next catalyst update?
12 months
What is your next catalyst (value inflection) update?
Clinical Proof of Concept
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}